ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.

Trial Details

NCT ID
NCT06800963
Phase
PHASE1 / PHASE2
Sponsor
ImmunityBio, Inc.
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Intravesical Recombinant Mycobacterium (rMBCG)
Locations (sample)
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Sacramento, California, United States|38.58157,-121.4944
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Troy, Michigan, United States|42.60559,-83.14993
  • Syracuse, New York, United States|43.04812,-76.14742

Key Eligibility Criteria

  • Participants must meet ALL of the following criteria for inclusion in the study:
  • Male or female participants 18 years of age or older.
  • Histologic confirmation of BCG naïve non-muscle invasive urothelial carcinoma of the bladder (mixed histology tumors allowed if urothelial histolog…
  • Absence of resectable disease after TURBT procedures (residual CIS acceptable; participants with T1 tumors must undergo repeat resection and biopsy…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →